Τίτλος:
Vascular risk factors and Alzheimer’s disease pathogenesis: Are conventional pharmacological approaches protective for cognitive decline progression?
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Alzheimer’s disease (AD) is the most common cause of dementia, accounting for more than half of cases with cognitive impairment. With numbers of patients expected to rise sharply over the following years in parallel with the ageing of population, there is intense clinical interest in discovering modifiable risk factors that may contribute to the increasing prevalence of AD. Accumulating data from in vitro and epidemiological studies have highlighted the vascular component of AD and raised hope that treatment of vascular risk factors could eventually lead to primary prevention of AD. Among all the possible pathologic processes that have been tested for an association with AD, diabetes, hypertension and dyslipidemia are the most prominent. Here, we will briefly review the data highlighting a potential correlation of these diseases with AD. Then, we will present observational studies and clinical trials that assessed the impact of their respective approved medical therapies on AD incidence. We conclude by providing clinical information for the physician on potentially effective and non-effective medical treatments. Further research is ongoing and time will show whether AD will cease to be considered a pure, non-preventable neurodegenerative process or whether vascular risk factor management may also result in primary AD prevention. © 2015 Bentham Science Publishers.
Συγγραφείς:
Safouris, A.
Psaltopoulou, T.
Sergentanis, T.N.
Boutati, E.
Kapaki, E.
Tsivgoulis, G.
Περιοδικό:
CNS and Neurological Disorders - Drug Targets
Εκδότης:
Bentham Science Publishers B.V.
Λέξεις-κλειδιά:
2, 4 thiazolidinedione derivative; antilipemic agent; atenolol; atorvastatin; calcium; candesartan; chlortalidone; enalapril; exendin 4; glucagon like peptide 1 receptor agonist; hydrochlorothiazide; hydroxymethylglutaryl coenzyme A reductase inhibitor; indapamide; losartan; metformin; mevinolin; nitrendipine; perindopril; pioglitazone; pravastatin; repaglinide; reserpine; rivastigmine; rosiglitazone; rosuvastatin; simvastatin; sulfonylurea derivative; telmisartan; unclassified drug, Alzheimer disease; Article; cardiovascular risk; cognition; cyanocobalamin deficiency; dementia; diabetes mellitus; diastolic blood pressure; disease association; disease duration; dyslipidemia; glucose blood level; human; hyperglycemia; hyperlipidemia; hypertension; meta analysis (topic); multicenter study (topic); nonhuman; randomized controlled trial (topic); risk factor; systematic review (topic); systolic blood pressure; vascular disease; Alzheimer disease; animal; Cardiovascular Diseases; Cognition Disorders; complication; disease course; pathophysiology; risk factor, Alzheimer Disease; Animals; Cardiovascular Diseases; Cognition Disorders; Disease Progression; Humans; Risk Factors
DOI:
10.2174/1871527314666150217123147
